Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swati Garg

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Antimicrobial Agents and Chemotherapy|November 14, 2022
Targeting Artemisinin-Resistant Malaria by Repurposing the Anti-Hepatitis C Virus Drug AlisporivirAyushi Chaurasiya, Geeta Kumari, Swati Garg, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II ConsortiumStephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Cell Death Discovery|January 14, 2021
Pathogen induced subversion of NAD<sup>+</sup> metabolism mediating host cell death: a target for development of chemotherapeuticsAyushi Chaurasiya, Swati Garg, Ashish Khanna, et al.
British Journal of Cancer|June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
Blood|May 12, 2019
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AMLSwati Garg, Armando Reyes-Palomares, Lixiazi He, et al.
EMBO Molecular Medicine|March 7, 2022
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemiaLixiazi He, Christian Arnold, Judith Thoma, et al.
Cancer Research Communications|March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian CancerStefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.
Journal of Human Immunity|May 22, 2026
Mendelian susceptibility to mycobacterial disease: Clinical, immunological, and genetic study in IndiaAparna Dalvi, Lavina Temkar, Mukesh Desai, et al.
Blood Cancer Journal|July 19, 2022
BRD9 degraders as chemosensitizers in acute leukemia and multiple myelomaEllen Weisberg, Basudev Chowdhury, Chengcheng Meng, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|November 14, 2022
Targeting Artemisinin-Resistant Malaria by Repurposing the Anti-Hepatitis C Virus Drug AlisporivirAyushi Chaurasiya, Geeta Kumari, Swati Garg, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II ConsortiumStephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Cell Death Discovery|January 14, 2021
Pathogen induced subversion of NAD<sup>+</sup> metabolism mediating host cell death: a target for development of chemotherapeuticsAyushi Chaurasiya, Swati Garg, Ashish Khanna, et al.
British Journal of Cancer|June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
Blood|May 12, 2019
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AMLSwati Garg, Armando Reyes-Palomares, Lixiazi He, et al.
EMBO Molecular Medicine|March 7, 2022
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemiaLixiazi He, Christian Arnold, Judith Thoma, et al.
Cancer Research Communications|March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian CancerStefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.
Journal of Human Immunity|May 22, 2026
Mendelian susceptibility to mycobacterial disease: Clinical, immunological, and genetic study in IndiaAparna Dalvi, Lavina Temkar, Mukesh Desai, et al.
Blood Cancer Journal|July 19, 2022
BRD9 degraders as chemosensitizers in acute leukemia and multiple myelomaEllen Weisberg, Basudev Chowdhury, Chengcheng Meng, et al.
Pageof 10